{"entity":{"id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","aka":[],"tldr":"A phase 1/2 trial of JL15003Injection in glioma & glioblastoma, run by Jecho Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) is a phase 1/2 interventional study registered as NCT07501559 by Jecho Biopharmaceuticals Co., Ltd., with 40 participants planned, started 2026-06-17 and due to reach its primary completion in 2030-04. Interventions recorded: JL15003Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07501559","url":"https://clinicaltrials.gov/study/NCT07501559"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07501559","phase":"1/2","setting":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","enrolled":40,"outcomes":[]},"route":"/trials/nct07501559/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}